Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional a...

Descripción completa

Detalles Bibliográficos
Autores principales: Grossmann, Liron D., Maris, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858281/
https://www.ncbi.nlm.nih.gov/pubmed/33314654
http://dx.doi.org/10.1002/1878-0261.12880
_version_ 1783646620482535424
author Grossmann, Liron D.
Maris, John M.
author_facet Grossmann, Liron D.
Maris, John M.
author_sort Grossmann, Liron D.
collection PubMed
description In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion.
format Online
Article
Text
id pubmed-7858281
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78582812021-02-05 Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles Grossmann, Liron D. Maris, John M. Mol Oncol Commentary In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion. John Wiley and Sons Inc. 2020-12-26 2021-02 /pmc/articles/PMC7858281/ /pubmed/33314654 http://dx.doi.org/10.1002/1878-0261.12880 Text en © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Grossmann, Liron D.
Maris, John M.
Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
title Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
title_full Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
title_fullStr Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
title_full_unstemmed Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
title_short Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
title_sort refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858281/
https://www.ncbi.nlm.nih.gov/pubmed/33314654
http://dx.doi.org/10.1002/1878-0261.12880
work_keys_str_mv AT grossmannlirond refiningimmunotherapeuticapproachestohighriskneuroblastomabasedontumorgenomicprofiles
AT marisjohnm refiningimmunotherapeuticapproachestohighriskneuroblastomabasedontumorgenomicprofiles

Ejemplares similares